Panos Konstantinopoulos, MD, PhD shares results of a phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer at the 2022 Society for Gynecologic Oncology Annual Meeting.
today at the S. G. O. Meeting I will be presenting a Phase two study of letrozole and automatically in estrogen receptor positive recurrent endometrial cancer. Endometrial cancer is the 6th most common cancer worldwide and it affects more than 400,000 women every year. One of the problems in this disease is that although a subset of hummus express estrogen receptor and can respond to hormonal therapy. Unfortunately, the responses are typically modest and relatively brief in duration. For this reason, development of novel strategies to improve the efficacy of endocrine therapy is an unmet need for this decision. The study that I am presenting today addresses exactly this problem and looks into a combination of Obama's signature, which is acidic. A 46 inhibitor. Together with endocrine therapy with an aromatase inhibitor called letrozole. In patients with endometrial cancer that is recurring and expresses the estrogen receptor. It is important to underscore that patients were allowed to have unlimited prior lines of therapy and could have had prior for monotherapy. Overall, we there were 30 patients that initiated protocol therapy and were evaluated as part of this study. We were able to see that 75% of these patients had either shrinkage of their tumors or stability of their disease. And of note, about 30% of these patients had at least 30% shrinkage of the stuff of their tumors. Importantly we have had patients stay on this treatment for more than two years and overall uh 55.6% of patients were without their disease progressing at six months. These are really, really good numbers and our study clearly met the pre specified criteria for this regimen to be considered worthy of further evaluation of in this setting.